Related Experiment Video
Updated: Feb 14, 2026

Assessing Cellular Target Engagement by SHP2 PTPN11 Phosphatase Inhibitors
Published on: July 17, 2020
Optimized peptide based inhibitors targeting the dihydrofolate reductase pathway in cancer
Amrinder Singh1, Neha Deshpande2, Nilkamal Pramanik3
1NMR Research Centre, Indian Institute of Science, Bangalore, 560012, India.
Abstract:
We report the first peptide based hDHFR inhibitors designed on the basis of structural analysis of dihydrofolate reductase (DHFR). A set of peptides were rationally designed and synthesized using solid phase peptide synthesis and characterized using nuclear magnetic resonance and enzyme immunoassays. The best candidate among them, a tetrapeptide, was chosen based on molecular mechanics calculations and evaluated in human lung adenocarcinoma cell line A549. It showed a significant reduction of cell proliferation and an IC50 of 82 µM was obtained. The interaction of the peptide with DHFR was supported by isothermal calorimetric experiments revealing a dissociation constant Kd of 0.7 µM and ΔG of -34 ± 1 kJ mol-1. Conjugation with carboxylated polystyrene nanoparticles improved further its growth inhibitory effects. Taken together, this opens up new avenues to design, develop and deliver biocompatible peptide based anti-cancer agents.
Related Concept Videos
Targeted Cancer Therapies
There are several types of targeted therapies against...
Peptide Bonds
Eukaryotic Transcription Inhibitors
Eukaryotic transcription inhibitors usually contain two distinct domains, a...
C4 Pathway and CAM
C4 Pathway
The C4 pathway is used by plants such as...
Optimal Foraging
Optimization Problems

